ArticleNuclear medicine and biology

Preclinical studies of a PARP targeted, Meitner-Auger emitting, theranostic radiopharmaceutical for metastatic ovarian cancer.

S L V Hoffman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.